FP008 has cleared an Investigational New Drug (IND) application with the U.S. FDA and China NMPA. Phase I clinical trial is currently ongoing with readout expected later this year. FP008 represents a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback